--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October, 2008
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, Co. Wicklow
Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No X
If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b): 82-_____________
================================================================================
TRINITY BIOTECH PLC
6-K Item
Press Release dated October 6, 2008
TRINITY BIOTECH
FOR RELEASE Monday October 6th, 2008
TRINITY BIOTECH EXECUTIVE CHAIRMAN
TO RESUME ROLE OF CEO
DUBLIN, Ireland (October 6th, 2008) Trinity Biotech plc (NASDAQ: TRIB), a
leading developer and manufacturer of diagnostic products for the point-of-care
and clinical laboratory markets, today announced that Mr. Ronan O'Caoimh,
Executive Chairman, has agreed to resume the role of CEO. Mr. O'Caoimh will
succeed Mr. Brendan Farrell, who has resigned with immediate effect, having
served as Trinity Biotech's President since 1994 and as CEO since November 2007.
Ronan O'Caoimh commented "I am hugely excited by this challenge and, given our
product offering and development pipeline, am determined to deliver on our
enormous potential for enhanced shareholder value."
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems,
including both reagents and instrumentation, for the point-of-care and clinical
laboratory segments of the diagnostic market. The products are used to detect
infectious diseases and blood coagulation disorders, and to quantify the level
of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole
blood. Trinity Biotech sells direct in the United States, Germany, France and
the U.K. and through a network of international distributors and strategic
partners in over 75 countries worldwide. For further information please see the
Company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the "safe
harbor" provision of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States Food and Drug
Administration and other agencies, the impact of competitive products, product
development commercialization and technological difficulties, and other risks
detailed in the Company's periodic reports filed with the Securities and
Exchange Commission.
Contact: Trinity Biotech plc Joe Diaz, Joe Dorame, Robert Blum
Ms. Niamh Long Lytham Partners, LLC
Investor Relations Officer (602) 889-9700
(353)-1-2769800
niamh.long@trinitybiotech.com
END OF RELEASE
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
TRINITY BIOTECH PLC
-------------------
(Registrant)
By: /s/ Kevin Tansley
-----------------
Kevin Tansley
Chief Financial Officer
Date: October 7, 2008